The mean MTX dose was 20 mg/week, with an average treatment duration ... T he mean follow-up duration was 5.7 years. Methotrexate was continued in 21 of 32 patients following the initial ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Long-term glucocorticoid (GC) use among older adults with late-onset rheumatoid arthritis (LORA) remains prevalent, despite its known adverse effects, according to study results published in ACR Open ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

Methods Early, biologic and MTX-naive RA patients (N=395) were evenly randomised to open-label adalimumab (40 mg every other week) plus weekly blinded 2.5, 5, 10 or 20 mg MTX for 26 weeks. Clinical, ...

Patients in the long-term extension, including 47 from the DARWIN 1 placebo arm, received 200 mg of filgotinib daily ... 497 from the methotrexate trial and 242 from the monotherapy trial.

Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort ...

In a 2020 clinical trial comparing the effectiveness of a low dose oral formulation (1 milligram [mg]) to the 5% formulation ... medications like methotrexate. It’s typically combined with ...

Patients receiving MTX were started at 10 mg/week, which was increased to 20 mg by week 8 if tolerated. In patients for whom a lower dose was indicated/required, an initial dose of 7.5 mg/week was ...

14 The percentage of patients with moderate disease activity (MDA, defined as DAS28-ESR≥3.2 to ≤5.1) in the ETN+MTX and MTX groups was 21/265 (7.9%) and 20/263 (7.6%), respectively. The PRIZE study ...

NOT satisfying ALL of the following criteria: AJC=0 AND ESR <13 mm/hour AND CRP <10 mg/L AND PGA=0 ... respectively (table 5). The capability of the ACR-CPG as prognostic test at 3 and 6 months to ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...